Brokers Set Expectations for Celator Pharmaceuticals Inc’s Q1 2016 Earnings (CPXX)

Posted by ABMN Staff on Mar 23rd, 2016

Celator Pharmaceuticals Inc (NASDAQ:CPXX) – Analysts at Roth Capital upped their Q1 2016 earnings per share (EPS) estimates for shares of Celator Pharmaceuticals in a research report issued to clients and investors on Monday, according to Zacks Investment Research. Roth Capital analyst J. Pantginis now expects that the firm will post earnings per share of ($0.15) for the quarter, up from their previous forecast of ($0.16). Roth Capital currently has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Celator Pharmaceuticals’ Q1 2016 earnings is ($0.16) per share. Roth Capital also issued estimates for Celator Pharmaceuticals’ Q2 2016 earnings at ($0.14) EPS, Q3 2016 earnings at ($0.16) EPS, Q4 2016 earnings at ($0.16) EPS, FY2016 earnings at ($0.60) EPS and FY2017 earnings at ($0.72) EPS.

CPXX has been the subject of several other reports. Janney Montgomery Scott initiated coverage on shares of Celator Pharmaceuticals in a research report on Tuesday, March 15th. They issued a “buy” rating and a $13.00 price objective for the company. HC Wainwright boosted their price objective on shares of Celator Pharmaceuticals to $20.00 and gave the company a “buy” rating in a research report on Tuesday, March 15th. Five equities research analysts have rated the stock with a buy rating, Celator Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $15.25.

Shares of Celator Pharmaceuticals (NASDAQ:CPXX) traded up 18.88% during midday trading on Wednesday, reaching $11.90. 11,287,548 shares of the company traded hands. The company’s market capitalization is $411.09 million. Celator Pharmaceuticals has a 1-year low of $1.12 and a 1-year high of $12.35. The company has a 50 day moving average price of $3.00 and a 200 day moving average price of $2.07.

Celator Pharmaceuticals (NASDAQ:CPXX) last issued its earnings results on Monday, March 21st. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by $0.01.

Celator Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing products to cure cancer. Celator’s technology platform, CombiPlex, offers the rational design and rapid evaluation of combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity.